Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

IL-33 attenuates the development of experimental autoimmune uveitis.

Barbour M, Allan D, Xu H, Pei C, Chen M, Niedbala W, Fukada SY, Besnard AG, Alves-Filho JC, Tong X, Forrester JV, Liew FY, Jiang HR.

Eur J Immunol. 2014 Nov;44(11):3320-9. doi: 10.1002/eji.201444671. Epub 2014 Oct 18.

2.

Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.

Keino H, Watanabe T, Sato Y, Niikura M, Wada Y, Okada AA.

Arthritis Res Ther. 2008;10(5):R122. doi: 10.1186/ar2530. Epub 2008 Oct 13.

3.

IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages.

Jiang HR, Milovanović M, Allan D, Niedbala W, Besnard AG, Fukada SY, Alves-Filho JC, Togbe D, Goodyear CS, Linington C, Xu D, Lukic ML, Liew FY.

Eur J Immunol. 2012 Jul;42(7):1804-14. doi: 10.1002/eji.201141947. Epub 2012 Jun 12.

4.

SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis (EAU).

Vistica BP, Shi G, Nugent L, Tan C, Altman A, Gery I.

Mol Vis. 2012;18:1858-64. Epub 2012 Jul 7.

5.

Oral administration of retinoic acid receptor-alpha/beta-specific ligand Am80 suppresses experimental autoimmune uveoretinitis.

Keino H, Watanabe T, Sato Y, Okada AA.

Invest Ophthalmol Vis Sci. 2011 Mar 1;52(3):1548-56. doi: 10.1167/iovs.10-5963.

PMID:
20861477
6.

Activation of liver X receptor alleviates ocular inflammation in experimental autoimmune uveitis.

Yang H, Zheng S, Qiu Y, Yang Y, Wang C, Yang P, Li Q, Lei B.

Invest Ophthalmol Vis Sci. 2014 Apr 28;55(4):2795-804. doi: 10.1167/iovs.13-13323.

8.

CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.

Iwahashi C, Fujimoto M, Nomura S, Serada S, Nakai K, Ohguro N, Nishida K, Naka T.

Exp Eye Res. 2015 Nov;140:53-64. doi: 10.1016/j.exer.2015.08.012. Epub 2015 Aug 20.

PMID:
26297802
9.

Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype.

Milovanovic M, Volarevic V, Ljujic B, Radosavljevic G, Jovanovic I, Arsenijevic N, Lukic ML.

PLoS One. 2012;7(9):e45225. doi: 10.1371/journal.pone.0045225. Epub 2012 Sep 18.

10.

Anti-inflammatory effect of retinoic acid on experimental autoimmune uveoretinitis.

Keino H, Watanabe T, Sato Y, Okada AA.

Br J Ophthalmol. 2010 Jun;94(6):802-7. doi: 10.1136/bjo.2009.171314. Epub 2009 Dec 3.

PMID:
19965837
11.

Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.

Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR.

J Immunol. 1998 Jul 1;161(1):122-7.

12.

IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.

Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, Caspi RR.

J Immunol. 1997 Jun 15;158(12):5997-6005.

PMID:
9190954
13.

[Effects of leflunomide on experimental autoimmune uveitis in Lewis rats].

Fang C, Zhou D, Zhan S, He Y, Lin Z, Huang C, Li J.

Zhonghua Yan Ke Za Zhi. 2015 Oct;51(10):754-61. Chinese.

PMID:
26693771
14.

Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.

Xu H, Strassmann G, Chan CC, Rizzo LV, Silver PB, Wiggert B, Caspi RR.

Invest Ophthalmol Vis Sci. 1999 Apr;40(5):942-50.

PMID:
10102291
15.

The Microbiota Determines Susceptibility to Experimental Autoimmune Uveoretinitis.

Heissigerova J, Seidler Stangova P, Klimova A, Svozilkova P, Hrncir T, Stepankova R, Kverka M, Tlaskalova-Hogenova H, Forrester JV.

J Immunol Res. 2016;2016:5065703. doi: 10.1155/2016/5065703. Epub 2016 May 17.

17.
18.

Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.

Fang CB, Zhou DX, Zhan SX, He Y, Lin Z, Huang C, Li J.

PLoS One. 2013 Apr 23;8(4):e62071. doi: 10.1371/journal.pone.0062071. Print 2013.

19.

Subretinal transfection of chitosan-loaded TLR3-siRNA for the treatment of experimental autoimmune uveitis.

Chen S, Yan H, Sun B, Zuo A, Liang D.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):726-35. doi: 10.1016/j.ejpb.2013.09.005. Epub 2013 Sep 17.

PMID:
24055691
20.

Ex-vivo tolerogenic F4/80⁺ antigen-presenting cells (APC) induce efferent CD8⁺ regulatory T cell-dependent suppression of experimental autoimmune uveitis.

Hsu SM, Mathew R, Taylor AW, Stein-Streilein J.

Clin Exp Immunol. 2014 Apr;176(1):37-48. doi: 10.1111/cei.12243.

Supplemental Content

Support Center